echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > $2.4 billion anti-inflammatory and anti-rheumatic drug!

    $2.4 billion anti-inflammatory and anti-rheumatic drug!

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, the official website of CDE showed that Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical was accepted for imitation of tofacitib citrate sustained-release tablets of 3 types of applications


    Data show that tofacitib is the world's first small molecule targeted JAK kinase inhibitor developed by Pfizer for the treatment of rheumatoid arthritis.


    Global sales of tofacitib citrate in recent years (unit: billion U.


    Source: Mynet.


    According to data from Menet.


    Source: One-click search on Mi Nei.


    Only tofacitib citrate tablets are on the market for tofacitib, and more than 10 manufacturers include Pfizer, Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, Hunan Kelun Pharmaceuticals, etc.


    At present, 4 companies of tofacitib citrate sustained-release tablets have submitted listing applications for approval.


    Source: CDE official website, Minet database

    Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.